ZA200708159B - 1-Acetic acid-indole derivatives with PDG2 antagonist activity - Google Patents

1-Acetic acid-indole derivatives with PDG2 antagonist activity

Info

Publication number
ZA200708159B
ZA200708159B ZA200708159A ZA200708159A ZA200708159B ZA 200708159 B ZA200708159 B ZA 200708159B ZA 200708159 A ZA200708159 A ZA 200708159A ZA 200708159 A ZA200708159 A ZA 200708159A ZA 200708159 B ZA200708159 B ZA 200708159B
Authority
ZA
South Africa
Prior art keywords
pdg2
acetic acid
antagonist activity
indole derivatives
alkyl
Prior art date
Application number
ZA200708159A
Other languages
English (en)
Inventor
Armer Richard Edward
Hay Philip Andrew
Boyd Edward Andrew
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of ZA200708159B publication Critical patent/ZA200708159B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200708159A 2005-03-11 2007-09-21 1-Acetic acid-indole derivatives with PDG2 antagonist activity ZA200708159B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0505048.9A GB0505048D0 (en) 2005-03-11 2005-03-11 Compounds with PGD antagonist activity

Publications (1)

Publication Number Publication Date
ZA200708159B true ZA200708159B (en) 2009-11-25

Family

ID=34508918

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708159A ZA200708159B (en) 2005-03-11 2007-09-21 1-Acetic acid-indole derivatives with PDG2 antagonist activity

Country Status (27)

Country Link
US (1) US8044088B2 (fr)
EP (1) EP1856045B1 (fr)
JP (1) JP2008532990A (fr)
KR (1) KR20070116633A (fr)
CN (1) CN101166721A (fr)
AT (1) ATE442356T1 (fr)
AU (1) AU2006221784A1 (fr)
BR (1) BRPI0608732A2 (fr)
CA (1) CA2601980A1 (fr)
CY (1) CY1109532T1 (fr)
DE (1) DE602006009080D1 (fr)
DK (1) DK1856045T3 (fr)
ES (1) ES2333161T3 (fr)
GB (1) GB0505048D0 (fr)
HK (1) HK1109628A1 (fr)
HR (1) HRP20090654T1 (fr)
IL (1) IL185844A0 (fr)
MX (1) MX2007011091A (fr)
NO (1) NO20074641L (fr)
NZ (1) NZ561747A (fr)
PL (1) PL1856045T3 (fr)
PT (1) PT1856045E (fr)
RS (1) RS51016B (fr)
RU (1) RU2007134456A (fr)
SI (1) SI1856045T1 (fr)
WO (1) WO2006095183A1 (fr)
ZA (1) ZA200708159B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
ES2618352T3 (es) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
SI2051962T1 (sl) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
DE602008005796D1 (de) 2007-12-14 2011-05-05 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US8470594B2 (en) * 2008-04-15 2013-06-25 President And Fellows Of Harvard College Methods for identifying agents that affect the survival of motor neurons
US9180114B2 (en) 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
PT2401269E (pt) * 2009-02-24 2014-03-11 Merck Canada Inc Derivados de indol como antagonistas de recetor crth2
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
LT2697223T (lt) 2011-04-14 2016-10-10 Actelion Pharmaceuticals Ltd. 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas
LT2781508T (lt) * 2011-11-17 2019-03-12 Kbp Biosciences Co., Ltd. Azoto turintys kondensuoti žiediniai junginiai, skirti panaudoti kaip crth2 antagonistai
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP3382391A1 (fr) 2012-10-24 2018-10-03 NYU Winthrop Hospital Biomarqueur non invasif pour identifier des sujets à risque d'accouchement prématuré
KR102116978B1 (ko) 2013-10-07 2020-05-29 삼성전자 주식회사 그래핀 소자 및 그 제조 방법
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3256121B1 (fr) 2015-02-13 2024-08-07 INSERM - Institut National de la Santé et de la Recherche Médicale Antagonistes ptgdr-1 et/ou ptgdr-2 pour la prévention et/ou le traitement du lupus érythémateux systémique
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ， インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
CN109180691B (zh) * 2018-08-24 2020-07-10 武汉大学 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN113425714B (zh) * 2021-08-04 2022-04-26 华南师范大学 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用
CN114870018A (zh) * 2022-05-12 2022-08-09 江南大学 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
WO2024192765A1 (fr) * 2023-03-23 2024-09-26 Brown University Utilisation de première classe de l'antagoniste de crth2 dans le traitement d'un trouble du spectre de la neuromyélite optique (nmosd) et de troubles du snc auto-immuns pertinents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
CN1205207C (zh) 1998-03-31 2005-06-08 药品发现学会公司 取代的吲哚链烷酸
JP4484108B2 (ja) * 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
DK2046740T3 (da) 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
DE602008005796D1 (de) 2007-12-14 2011-05-05 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (fr) 2008-01-22 2010-12-29 Oxagen Limited Composés présentant une activité antagoniste du récepteur crth2
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
RS51016B (sr) 2010-10-31
PL1856045T3 (pl) 2010-02-26
PT1856045E (pt) 2009-12-09
KR20070116633A (ko) 2007-12-10
NO20074641L (no) 2007-11-01
HK1109628A1 (en) 2008-06-13
EP1856045A1 (fr) 2007-11-21
ES2333161T3 (es) 2010-02-17
ATE442356T1 (de) 2009-09-15
US20100330077A1 (en) 2010-12-30
DK1856045T3 (da) 2010-01-04
CY1109532T1 (el) 2014-08-13
WO2006095183A1 (fr) 2006-09-14
GB0505048D0 (en) 2005-04-20
DE602006009080D1 (de) 2009-10-22
CA2601980A1 (fr) 2006-09-14
EP1856045B1 (fr) 2009-09-09
JP2008532990A (ja) 2008-08-21
IL185844A0 (en) 2008-01-06
AU2006221784A1 (en) 2006-09-14
BRPI0608732A2 (pt) 2016-11-08
SI1856045T1 (sl) 2010-01-29
CN101166721A (zh) 2008-04-23
US8044088B2 (en) 2011-10-25
NZ561747A (en) 2010-03-26
MX2007011091A (es) 2007-11-22
HRP20090654T1 (hr) 2010-01-31
RU2007134456A (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
ZA200708159B (en) 1-Acetic acid-indole derivatives with PDG2 antagonist activity
GB0510584D0 (en) Organic compounds
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DK1755590T3 (da) Kombination af glycopyrrolat og en beta2-adrenoceptoragonist
DE60317326D1 (de) Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2006029154A3 (fr) Nouveaux composes
WO2009028387A1 (fr) Agent thérapeutique pour le cancer avec une résistance à l'inhibiteur de la protéase
MY140666A (en) Biotinylated hexadecasaccharides, preparation and use thereof
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
UA97957C2 (ru) 2-{5-фтор-2-метил-3-[2-(фенилсульфонил)бензил]-1н-индол-1-ил}уксусная кислота и ее производные, их применение для лечения заболеваний, опосредствованных действием pgd2 на рецептор crth2